Over the forecast period, a rise in the use of inorganic growth techniques, such as key companies working together to develop paediatric antibiotics, is anticipated to fuel the expansion of the worldwide paediatric antibiotics market. For instance, in April 2020, the Global Antibiotic Research and Development Partnership (GARDP), a not-for-profit research and development (R&D) organisation, and Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company, announced a collaboration to quicken the development of and access to cefepime-taniborbactam (previously known as cefepime/VNRX-5133). Cefepime-taniborbactam is a novel, broad-spectrum beta-lactamase inhibitor that restores the activity of cefepime against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA). It is an investigational combination of the fourth-generation antibiotic cefepime. To finish the complex urinary tract infection (cUTI) phase 3 trial for cefepime-taniborbactam, GARDP will work with Venatorx.
The market for Paediatric Antibiotics is anticipated to reach a value of US$6,478.9 million in 2022 and is predicted to grow at a CAGR of 2.3% from 2022 to 2030.
Prominent Companies in the Pediatric Antibiotics Industry:
1. Johnson & Johnson:
Johnson & Johnson Development - JJDC - was a venture capital fund run by Johnson & Johnson Innovation. The fund is based in New Brunswick, New Jersey, and it makes investments in the United States. It focused on healthcare devices and supplies, pharmaceuticals and biotechnology, and life science. The company was founded in 1978. In 1978, the headquarters were established. Johnson & Johnson's Janssen Pharmaceutical Companies announced in 2020 that it will expand its existing collaboration with the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, to seek treatment solutions for COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2.
